© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
September 20, 2020
Apatinib in combination with gefitinib in the first-line setting demonstrated superior progression-free survival (PFS) in patients with advanced EGFR-mutant non–small cell lung cancer.
September 19, 2020
The first-in-class inhibitor of apoptosis protein (IAP) antagonist significantly improved overall survival in patients with LA-SCCHN.
Induction avelumab prior to standard of care led to a clinically relevant worsening of survival as the first-line treatment for patients with metastatic urothelial carcinoma.
June 03, 2020
Belantamab mafodotin monotherapy induced durable responses and appeared to be well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.